Literature DB >> 18850011

Inhibition of Siah ubiquitin ligase function.

A Möller1, C M House, C S F Wong, D B Scanlon, M C P Liu, Z Ronai, D D L Bowtell.   

Abstract

Tumor hypoxia induces the upregulation of hypoxia-inducible factor 1alpha (Hif-1alpha), which in turn induces the expression of genes including VEGF to recruit new blood vessel outgrowth, enabling tumor growth and metastasis. Interference with the Hif-1 pathway and neoangiogenesis is an attractive antitumor target. The hydroxylation of Hif-1alpha by prolyl-hydroxylase (PHD) proteins during normoxia serves as a recognition motif for its proteasomal degradation. However, under hypoxic conditions, hydroxylation is inhibited and furthermore, PHD proteins are themselves polyubiquitylated and degraded by Siah ubiquitin ligases. Our data demonstrate for the first time that inhibition of the interaction between Siah and PHD proteins using a fragment derived from a Drosophila protein (phyllopod) interferes with the PHD degradation. Furthermore, cells stably expressing the phyllopod fragment display reduced upregulation of Hif-1alpha protein levels and Hif-1-mediated gene expression under hypoxia. In a syngeneic mouse model of breast cancer, the phyllopod fragment reduced tumor growth and neoangiogenesis and prolonged survival of the mice. In addition, levels of Hif-1alpha and its target Glut-1 are reduced in tumors expressing the phyllopod fragment. These data show, in a proof-of-principle study, that Siah protein, the most upstream component of the hypoxia pathway yet identified, is a viable drug target for antitumor therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18850011      PMCID: PMC3000903          DOI: 10.1038/onc.2008.382

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  The ubiquitin ligase component Siah1a is required for completion of meiosis I in male mice.

Authors:  Ross A Dickins; Ian J Frew; Colin M House; Moira K O'Bryan; Andrew J Holloway; Izhak Haviv; Nadia Traficante; David M de Kretser; David D L Bowtell
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 2.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

Authors:  Michael H Glickman; Aaron Ciechanover
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

3.  A binding motif for Siah ubiquitin ligase.

Authors:  Colin M House; Ian J Frew; Huei-Luen Huang; Gerhard Wiche; Nadia Traficante; Edouard Nice; Bruno Catimel; David D L Bowtell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

4.  Generation and analysis of Siah2 mutant mice.

Authors:  Ian J Frew; Vicki E Hammond; Ross A Dickins; Julian M W Quinn; Carl R Walkley; Natalie A Sims; Ralf Schnall; Neil G Della; Andrew J Holloway; Matthew R Digby; Peter W Janes; David M Tarlinton; Louise E Purton; Matthew T Gillespie; David D L Bowtell
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

5.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

6.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

7.  SIAH-1 interacts with CtIP and promotes its degradation by the proteasome pathway.

Authors:  Antonia Germani; Audrey Prabel; Samia Mourah; Marie-Pierre Podgorniak; Anna Di Carlo; Ricardo Ehrlich; Sylvie Gisselbrecht; Nadine Varin-Blank; Fabien Calvo; Heriberto Bruzzoni-Giovanelli
Journal:  Oncogene       Date:  2003-12-04       Impact factor: 9.867

8.  Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2.

Authors:  Steven J Freedman; Zhen-Yu J Sun; Andrew L Kung; Dennis S France; Gerhard Wagner; Michael J Eck
Journal:  Nat Struct Biol       Date:  2003-07

9.  Modulation of transforming growth factor beta (TGFbeta)/Smad transcriptional responses through targeted degradation of TGFbeta-inducible early gene-1 by human seven in absentia homologue.

Authors:  Steven A Johnsen; Malayannan Subramaniam; David G Monroe; Ralf Janknecht; Thomas C Spelsberg
Journal:  J Biol Chem       Date:  2002-06-18       Impact factor: 5.157

10.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.

Authors:  David Lando; Daniel J Peet; Jeffrey J Gorman; Dean A Whelan; Murray L Whitelaw; Richard K Bruick
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

View more
  36 in total

1.  Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation.

Authors:  Claus-Henning Nagel; Nina Albrecht; Kristijana Milovic-Holm; Lakshmikanth Mariyanna; Britta Keyser; Bettina Abel; Britta Weseloh; Thomas G Hofmann; Martha M Eibl; Joachim Hauber
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  The ubiquitin ligase Siah2 and the hypoxia response.

Authors:  Koh Nakayama; Jianfei Qi; Ze'ev Ronai
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

3.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

4.  Distinct expression patterns of the E3 ligase SIAH-1 and its partner Kid/KIF22 in normal tissues and in the breast tumoral processes.

Authors:  Heriberto Bruzzoni-Giovanelli; Plinio Fernandez; Lucía Veiga; Marie-Pierre Podgorniak; Darren J Powell; Marco M Candeias; Samia Mourah; Fabien Calvo; Mónica Marín
Journal:  J Exp Clin Cancer Res       Date:  2010-02-09

Review 5.  The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities.

Authors:  Jianfei Qi; Maurizio Pellecchia; Ze'ev A Ronai
Journal:  Oncotarget       Date:  2010-09

6.  Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis.

Authors:  Meera Shah; John L Stebbins; Antimone Dewing; Jianfei Qi; Maurizio Pellecchia; Ze'ev A Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-27       Impact factor: 4.693

Review 7.  Regulators and effectors of Siah ubiquitin ligases.

Authors:  Jianfei Qi; Hyungsoo Kim; Marzia Scortegagna; Ze'ev A Ronai
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

8.  SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.

Authors:  Kimberly D van der Willik; Mieke M Timmermans; Carolien Hm van Deurzen; Maxime P Look; Esther A Reijm; Wendy Jhp van Zundert; Renée Foekens; Anita Mac Trapman-Jansen; Michael A den Bakker; Pieter J Westenend; John Wm Martens; Els Mjj Berns; Maurice Phm Jansen
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

9.  Structure-based design of covalent Siah inhibitors.

Authors:  John L Stebbins; Eugenio Santelli; Yongmei Feng; Surya K De; Angela Purves; Khatereh Motamedchaboki; Bainan Wu; Ze'ev A Ronai; Robert C Liddington; Maurizio Pellecchia
Journal:  Chem Biol       Date:  2013-07-25

10.  Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

Authors:  Sreenivasulu Chintala; Károly Tóth; Shousong Cao; Farukh A Durrani; Mary M Vaughan; Randy L Jensen; Youcef M Rustum
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.